ADXS Advaxis Inc.

0.35
+0.02  (+7%)
Previous Close 0.33
Open 0.33
Price To Book 0.18
Market Cap 8,648,547
Shares 24,710,135
Volume 4,239,422
Short Ratio
Av. Daily Volume 6,569,940
Stock charts supplied by TradingView

NewsSee all news

  1. Advaxis and UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery Research

    Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a research collaboration agreement with the

  2. Advaxis Announces Updated Prolonged Survival Data in Phase 1/2 ADXS-PSA Trial

     Median overall survival for ADXS-PSA in combination with KEYTRUDA® increased to 33.6 months from previously reported 21.1 months Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the

  3. Advaxis Reports Fiscal Third Quarter 2019 Financial Results and Provides Pipeline Update

    Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced an update on its clinical pipeline and financial

  4. Advaxis, Inc. Issues Letter to Shareholders

    Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that its chief executive officer, Kenneth A.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Enrollment to be terminated - noted November 2, 2018.
Axalimogene filolisbac + durvalumab
Recurrent or refractory HPV-associated cervical cancer and head & neck cancer
Phase 1 updated data noted median overall survival of 33.6 months - October 7, 2019.
ADXS-PSA and Keytruda - KEYNOTE-046
Castrate-resistant prostate cancer
Phase 3 trial closed - noted June 27, 2019.
Axalimogene filolisbac - AIM2CERV Trial
High-risk, locally advanced cervical cancer
Decided not to proceed to the expansion phase of the trial - noted in 10K December 21, 2017.
ADXS-HER2
HER2-driven malignancies - cancer
Noted in 10-K December 21, 2017 that it will not initiate the Stage 2 portion of the trial in order to focus its resources on other clinical priorities.
Axalimogene filolisbac
Anal cancer (FAWCETT)
Phase 1 safety and immunogenicity data presented at AACR March 2019
ADXS-NEO
Non-small cell lung cancer (NSCLC)
Phase 1/2 preliminary data due 2H 2019.
ADXS-HOT 503
Non-small cell lung cancer (NSCLC)

Latest News

  1. Advaxis and UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery Research

    Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a research collaboration agreement with the

  2. Advaxis Announces Updated Prolonged Survival Data in Phase 1/2 ADXS-PSA Trial

     Median overall survival for ADXS-PSA in combination with KEYTRUDA® increased to 33.6 months from previously reported 21.1 months Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the

  3. Advaxis Reports Fiscal Third Quarter 2019 Financial Results and Provides Pipeline Update

    Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced an update on its clinical pipeline and financial

  4. Advaxis, Inc. Issues Letter to Shareholders

    Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that its chief executive officer, Kenneth A.